MCID: TST043
MIFTS: 35

Testicular Seminoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Testicular Seminoma

MalaCards integrated aliases for Testicular Seminoma:

Name: Testicular Seminoma 52 17
Testicular Seminomatous Germ Cell Tumor 52
Seminomatous Germ Cell Tumor of Testis 52
Seminoma of Testis 52
Seminoma 71

Classifications:



External Ids:

UMLS 71 C0036631

Summaries for Testicular Seminoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 842 Definition Testicular seminomatous germ cell tumor is a rare testicular germ cell tumor (see this term), most commonly presenting with a painless mass in the scrotum, with a very high cure rate if caught in the early stages. Epidemiology Annual incidence in Europe is 1/62,000 people. It accounts for 40% of testicular cancer cases. Clinical description Seminoma usually presents in males between the ages of 30-40. A painless mass in the scrotum is indicative of disease. A long-standing hydrocele may be noted causing a feeling of heaviness in the testicle. Gynecomastia and back and flank pain are symptoms that are seen in some patients. Relapse after surgery can occur, usually (in 97% of cases) in the high iliac or retroperitoneal lymph nodes . Metastasis , although rare, can occur in some cases, affecting the lungs, liver, bones and central nervous system . Etiology Etiology is unknown but tumors are thought to arise from an embryonic germ cell leading to testicular intraepithelial neoplasia (the precursor to classical seminoma). Cryptorchidism is a risk factor for the development of testicular seminomatous germ cell tumors. Diagnostic methods Ultrasound usually confirms the presence of a testicular mass. Measurement of tumor markers in blood such as alpha-fetoprotein (AFP), beta human chorionic gonadotropin (BHC) and lactate dehydrogenase (LDH) is needed as it can be useful in cases where the tumor is still very small. Classical seminoma does not secrete AFP and patients with raised levels of this tumor marker are given a diagnosis of non-seminoma. After surgical removal of testicle, histopathological characteristics are analyzed and a stage can be assigned. In stage 1 disease the primary tumor is limited to the testis and epididymus with possible invasion of the tunica albuginea, tunica vaginalis, spermatic cord and scrotum but no lymph node or distant metastasis. Stage 2 (2A, 2B and 2C) disease features regional lymph node metastasis and stage 3 has distant metastasis of varying degrees. Differential diagnosis Testicular non seminomatous germ cell tumors (see this term) must be excluded. Management and treatment Treatment for stage 1 seminoma involves an orchiectomy or partial orchiectomy in some cases. Most patients (88%) do not require any further treatment and only surveillance is necessary. In those cases where follow up is difficult, adjuvant carboplatin or radiotherapy can be applied. Para-aortic and ipsilateral iliac radiotherapy (30 Gy in 2 Gy fractions) is the standard treatment of stage 2A seminoma. Cisplatin, etoposide and bleomycin (PEB) chemotherapy (three cycles) or cisplatin and etoposide (PE) chemotherapy (4 cycles) is an alternative to radiotherapy (but has more acute toxicity). Those with stage 2B, 2C and stage 3 seminomas are given PEB chemotherapy (three or four cycles depending on prognosis ). In those with a reduced lung capacity or with emphysema or in severe smokers, 4 cycles of PE is preferred over PEB. Ifosfamide is given instead of bleomycin in certain cases (i.e. patients with existing lung damage). Follow up and sometimes a PET scan is recommended to monitor for residual lesions. Due to cosmetic and psychological reasons, patients may be offered testicular prostheses after an orchidectomy. Prognosis Prognosis is good but depends on the stage of disease with 5- year survival rates as high as 99% in stage 1 disease. Relapse rates at 5 years depend on risk factors (ex. invasion of the rete testis, tumor size >4cm) present, but is only 12% in those with no risk factors. Visit the Orphanet disease page for more resources.

MalaCards based summary : Testicular Seminoma, also known as testicular seminomatous germ cell tumor, is related to testicular germ cell tumor and seminoma. An important gene associated with Testicular Seminoma is TSPY1 (Testis Specific Protein Y-Linked 1), and among its related pathways/superpathways are Peptide hormone metabolism and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Granisetron and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include testis, lymph node and bone.

Related Diseases for Testicular Seminoma

Diseases related to Testicular Seminoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 testicular germ cell tumor 31.9 CGB3 AFP
2 seminoma 30.4 TSPY1 CGB3 CGA AFP
3 germ cell cancer 30.1 CGA AFP
4 testicular cancer 30.1 CGB3 CGA AFP
5 cryptorchidism, unilateral or bilateral 30.0 CGA AFP
6 hydrocele 29.6 CGA AFP
7 endodermal sinus tumor 29.6 CGB3 AFP
8 teratoma 29.6 CGB3 CGA AFP
9 gonadoblastoma 29.5 TSPY1 CGB3
10 germinoma 29.4 CGB3 CGA AFP
11 choriocarcinoma 29.4 CGB3 CGA
12 chromosomal triplication 29.3 CGB3 AFP
13 embryonal carcinoma 29.3 CGB3 AFP
14 tubular variant testicular seminoma 12.4
15 cribriform variant testicular seminoma 12.4
16 pseudoglandular variant testicular seminoma 12.4
17 testis seminoma 11.7
18 germ cells tumors 10.6
19 testicular germ cell cancer 10.5
20 spermatocytoma 10.4
21 testicular spermatocytic seminoma 10.4
22 peptic ulcer disease 10.3
23 in situ carcinoma 10.3
24 nonseminomatous germ cell tumor 10.3
25 testicular torsion 10.2
26 persistent mullerian duct syndrome 10.2
27 infertility 10.2
28 pineal region germinoma 10.2
29 thyroid carcinoma 10.2
30 mature teratoma 10.2
31 renal cell carcinoma, nonpapillary 10.2
32 sarcoidosis 1 10.2
33 thymoma, familial 10.2
34 lymphoma 10.2
35 hydronephrosis 10.2
36 sarcoma 10.2
37 infant gynecomastia 10.2
38 neutropenia 10.2
39 gynecomastia 10.2
40 azoospermia 10.2
41 hypogonadism 10.2
42 thymoma 10.2
43 pseudohermaphroditism 10.2
44 pulmonary fibrosis 10.2
45 spindle cell sarcoma 10.2
46 myeloid leukemia 10.2
47 neuropathy 10.2
48 esophageal cancer 10.1
49 kaposi sarcoma 10.1
50 immune deficiency disease 10.1

Graphical network of the top 20 diseases related to Testicular Seminoma:



Diseases related to Testicular Seminoma

Symptoms & Phenotypes for Testicular Seminoma

Drugs & Therapeutics for Testicular Seminoma

Drugs for Testicular Seminoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Ondansetron Approved Phase 3 99614-02-5 4595
4
Captopril Approved Phase 3 62571-86-2 44093
5
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
6
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
8
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
9
Ribavirin Approved Phase 3 36791-04-5 37542
10
Palivizumab Approved, Investigational Phase 3 188039-54-5
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
12
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
13
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
14
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
15
Etoposide Approved Phase 3 33419-42-0 36462
16
Lenograstim Approved, Investigational Phase 3 135968-09-1
17
Mesna Approved, Investigational Phase 3 3375-50-6 598
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
20
Promethazine Approved, Investigational Phase 3 60-87-7 4927
21
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
22
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
23
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
24
Ifosfamide Approved Phase 3 3778-73-2 3690
25
Vinblastine Approved Phase 3 865-21-4 241903 13342
26 Gastrointestinal Agents Phase 3
27 Antiemetics Phase 3
28 Neurotransmitter Agents Phase 3
29 Anti-Infective Agents Phase 3
30 Immunosuppressive Agents Phase 3
31 Antiviral Agents Phase 3
32 Antimetabolites Phase 3
33 Antirheumatic Agents Phase 3
34 Cola Phase 3
35 Hormones Phase 3
36 Antineoplastic Agents, Hormonal Phase 3
37 Anti-Anxiety Agents Phase 3
38 Hormone Antagonists Phase 3
39 glucocorticoids Phase 3
40 Psychotropic Drugs Phase 3
41 Liver Extracts Phase 3
42 Dermatologic Agents Phase 3
43 Anti-Inflammatory Agents Phase 3
44 Antipsychotic Agents Phase 3
45 Antihypertensive Agents Phase 3
46 Angiotensin-Converting Enzyme Inhibitors Phase 3
47 HIV Protease Inhibitors Phase 3
48
protease inhibitors Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50
Hydroxyitraconazole Phase 3

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
2 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
3 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
4 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
5 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
6 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
7 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
8 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
9 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
10 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
11 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
14 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
15 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
16 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
17 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
18 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
19 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
20 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
21 PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER Completed NCT00002903 Phase 2 docetaxel
22 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
23 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
24 Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors Completed NCT01055067 Phase 2 Tivantinib (ARQ 197)
25 A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT Completed NCT02272816 Phase 2 Carboplatin AUC-10
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
28 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
29 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
30 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
31 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
32 Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients Completed NCT00423852 Phase 1, Phase 2 carboplatin;ifosfamide;paclitaxel
33 A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors Completed NCT00957905 Phase 2 Alvocidib Hydrochloride;Fluorouracil;Leucovorin Calcium;Oxaliplatin
34 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
35 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
36 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Recruiting NCT00432094 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel;thiotepa;Mesna
37 Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma Recruiting NCT01887340 Phase 2 Carboplatin;Etoposide;Cisplatin
38 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts Recruiting NCT03937843 Phase 2 Carboplatin;Cisplatin;Etoposide
39 A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors Recruiting NCT03158064 Phase 2 Durvalumab;Tremelimumab
40 A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Recruiting NCT02317393 Phase 2
41 Phase II Single-arm Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST) Recruiting NCT02797626 Phase 2
42 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
43 Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma Active, not recruiting NCT01593241 Phase 2 Carboplatin
44 A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma Terminated NCT00042952 Phase 2 imatinib mesylate
45 Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors Terminated NCT01808534 Phase 2 palifosfamide
46 Phase II Multi-institutional Proof of Concept Single-arm Trial of Nivolumab in the Treatment of Patients With Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Withdrawn NCT03726281 Phase 2 Nivolumab
47 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
48 A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors Completed NCT00313599 Phase 1 lapatinib;paclitaxel
49 CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
50 Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours: Potential Risks and Consequences for the Conceptus Unknown status NCT03262207

Search NIH Clinical Center for Testicular Seminoma

Genetic Tests for Testicular Seminoma

Anatomical Context for Testicular Seminoma

MalaCards organs/tissues related to Testicular Seminoma:

40
Testis, Lymph Node, Bone, Liver, Lung, Bone Marrow, Prostate

Publications for Testicular Seminoma

Articles related to Testicular Seminoma:

(show top 50) (show all 874)
# Title Authors PMID Year
1
Paraneoplastic tumefactive demyelination in a 47-year-old man with underlying seminoma. 61
32217464 2020
2
Clinical significance of Kelch-like protein 11 antibodies. 61
31953318 2020
3
Re: Classic Testicular Seminoma in Men Aged 50 Years or Over: A Case Report and Review of the Literature. 61
32401652 2020
4
Inhibition of Activin/Myostatin signalling induces skeletal muscle hypertrophy but impairs mouse testicular development. 61
32499882 2020
5
Testicular Seminoma Presenting with Bilateral Blindness: Looking Beyond the Eye. 61
32377482 2020
6
Supraclavicular left neck mass: an unusual presentation of metastatic testicular cancer in two older men. 61
32327457 2020
7
Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. 61
31818649 2020
8
Characterization and distribution of sialic acids in human testicular seminoma. 61
32143917 2020
9
Seminoma metastasized to the prostate: A case report and literature review. 61
31890599 2020
10
Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss. 61
31442315 2020
11
[Intimal sarcoma of pulmonary arteries]. 61
32008347 2020
12
Contemporary management of early stage testicular seminoma. 61
32055484 2020
13
Ominous Occurrence of Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumor Four Decades following Radiation Therapy for Testicular Seminoma. 61
32047679 2020
14
Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival. 61
31704139 2020
15
Re: Adjuvant Carboplatin Therapy in Patients with Clinical Stage 1 Testicular Seminoma: Is Long-Term Morbidity Increased? 61
31518193 2019
16
Pathological risk factors for metastatic disease at presentation in testicular seminomas with focus on the recent pT changes in AJCC TNM eighth edition. 61
31666197 2019
17
Changes in the telocyte/CD34+ stromal cell and α-SMA+ myoid cell networks in human testicular seminoma. 61
31540712 2019
18
Differentiation of testicular seminoma and nonseminomatous germ cell tumor on magnetic resonance imaging. 61
31702681 2019
19
Identification of potential core genes and miRNAs in testicular seminoma via bioinformatics analysis. 61
31545448 2019
20
Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor. 61
31381875 2019
21
Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased? 61
31286241 2019
22
Cardiac sarcoidosis in a patient with testicular seminoma. 61
31527203 2019
23
Expression of the immune checkpoint receptor TIGIT in seminoma. 61
31423216 2019
24
Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. 61
31182339 2019
25
Synthesis of a novel platinum(II) complex with 6,7-dichloro-5,8-quinolinedione and the study of its antitumor mechanism in testicular seminoma. 61
31055215 2019
26
[Clinicopathologic features of testicular seminoma with syncytiotrophoblastic cells: Analysis of 3 cases and review of the literature]. 61
32223107 2019
27
Granulomatous CNS inflammation associated with seminoma. 61
30859315 2019
28
Distinct clinical characteristics of paraneoplastic optic neuropathy. 61
30021813 2019
29
Late and Rapid Relapse in Mediastinum from Testicular Germ Cell Tumor Stage I Over 13 Years after Surgery. 61
31320874 2019
30
PET-CT for the management of testicular seminoma patients with post-chemotherapy residual masses. 61
31075095 2019
31
Re: Exploring the Spectrum of Late Effects following Radical Orchidectomy for Stage I Testicular Seminoma: . 61
30759675 2019
32
Leptin Receptor as a Potential Target to Inhibit Human Testicular Seminoma Growth. 61
30610844 2019
33
Poor prognosis of retroperitoneal mixed extragonadal germ cell tumors in an HIV-infected man with severe immunosuppression and bilateral cryptorchidism: a case report. 61
30885154 2019
34
Prominent right ventricular mass in a young patient with a history of classic testicular seminoma: a case report. 61
31020243 2019
35
Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature. 61
30350189 2019
36
Thymic inflammatory pseudotumor with multilocular thymic cyst caused by immunoglobulin G4-related disease. 61
30467988 2019
37
Ambiguous presentation of an intra-abdominal testicular seminoma in a 40-year-old man: a case report. 61
30609931 2019
38
Classic Testicular Seminoma in Men Aged 50 Years or Over: A Case Report and Review of the Literature. 61
31871817 2019
39
Management of Residual Mass in Germ Cell Tumors After Chemotherapy. 61
30666469 2019
40
Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study. 61
31616180 2019
41
Testicular Seminoma in a Transgender Woman: A Case Report. 61
30650051 2019
42
Prognostic factors for relapse in stage I testicular seminoma: tumor size and rete testis invasion revisited. 61
29744734 2018
43
Testicular seminoma in the aged rat visualized by phase-contrast X-ray computed tomography. 61
30377541 2018
44
Superior vena cava obstruction by metastatic mediastinal testicular seminoma. Imaging of collateral pathways during gastrointestinal bleeding scintigraphy with 99mTc labeled red blood cells. 61
29636233 2018
45
Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries. 61
29460991 2018
46
Persistent Mullerian Duct Syndrome with Testicular Seminoma in Transverse Testicular Ectopia. 61
30568363 2018
47
[Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin]. 61
30064153 2018
48
Primary mediastinal seminoma. 61
30174881 2018
49
Peritoneal Myeloid Sarcoma in a Patient Treated for a Testicular Seminoma. 61
29955031 2018
50
Current Practice Patterns Surrounding Fertility Concerns in Stage I Seminoma Patients: Survey of United States Radiation Oncologists. 61
29336660 2018

Variations for Testicular Seminoma

Expression for Testicular Seminoma

Search GEO for disease gene expression data for Testicular Seminoma.

GO Terms for Testicular Seminoma

Cellular components related to Testicular Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.26 CLU CGB3 CGA AFP
2 extracellular space GO:0005615 8.92 CLU CGB3 CGA AFP

Biological processes related to Testicular Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone processing GO:0016486 8.62 CGB3 CGA

Molecular functions related to Testicular Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 CGB3 CGA

Sources for Testicular Seminoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....